Despite a variety of treatments including radiotherapy, chemotherapy, vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors, and immune-checkpoint inhibitors to delay the progress of the disease, it is hard to select treatment strategies for patients with advanced cancer due to the frequently occurring severe side effects and intrinsic or acquired drug resistance of each treatment [4, 5]. The gene discussed is VEGFA; the disease is cancer.